Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological ... and other immune cells into the airways of animals in an asthma mouse model. Moreover, topical administration of the ...

Cytokine CXCL12 (also known as stromal-derived factor 1α) and its receptor CXCR4 represent the most promising actionable targets for this strategy. Both are overexpressed in various cancer types ...

Reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4/CXCL12 pathway can lead to neutropenia and lymphopenia, followed by frequent ...

These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

Recently, plerixafor (also called AMD3100), a small-molecule inhibitor of the CXC chemokine receptor 4 (CXCR4)–CXC chemokine ligand 12 (CXCL12) axis, was approved for stem-cell mobilization and ...

Human immunodeficiency virus (HIV) infection is a viral infection that causes acquired immunodeficiency syndrome (AIDS) by gradually destroying certain leukocytes. When HIV enters the human body ...

WHIM syndrome (characterized by warts, hypogammaglobulinemia, infections, and myelokathexis) is a rare immunodeficiency caused by inherited autosomal-dominant mutations in CXCR4 that confer gain ...

Our previous reports have focused on the tumor microenvironment in liver cancer, including the role of CXCR4, a receptor for CXCL12, which helps weaken the immune system's ability to fight cancer ...

Furthermore, they showed that they could slow disease progression in mice genetically engineered to develop T-ALL by inhibiting CXCL12--the major protein CXCR4 binds to. "Our experiments showed ...

combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4/CXCL12 pathway. People with WHIM ...

thereby resulting in a complete block of CXCL12 signaling through its two receptors, CXCR4 and CXCR7. Competing agents currently in clinical trials act at the receptor level and only inhibit CXCR4.